HIV Scientific Papers
Intramuscular ibalizumab: pharmacokinetics, safety, and efficacy vs IV administration.
2017
Lin H-H, Lee SS-J, Wang N-C, et al.
Poster #2181 presented at: Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington, USA.
Forty-eight-week safety and efficacy on-treatment analysis of ibalizumab in patients with multi-drug resistant HIV-1 [abstract].
2017
Open Forum Infect Dis.
Emu B, Fessel J, Schrader S, et al.
4(suppl 1):S38-S39. Proceedings of IDWeek, 2017.
Forty-eight-week safety and efficacy on-treatment analysis of ibalizumab in patients with multi-drug resistant HIV-1.
2017
Emu B.
Oral presentation #1686 at: IDWeek; Oct 4-8, 2017; San Diego, California, USA.
Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.
2017
AIDS.
Fourman LT, Czerwonka N, Feldpausch MN, et al.
31(16):2253-2259.
Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.
2017
Growth Horm IGF Res.
Braun LR, Feldpausch MN, Czerwonka N, et al.
37:1-6.